TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supervised Exercises Compared With Radial Extracorporal Shock Wave Therapy (rESWT) in Patients With Subacromial Impingement Syndrome: A Single Blind Clinical Randomized Study
Brief Summary: The purpose of this study is to compare Supervised Exercises with another non-operative frequently used treatment, Radial Extracorporeal Shockwave Therapy (rESWT), for patients with subacromial impingement syndrome.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Physical therapy method called Supervised Exercises | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radial Extracorporeal Shockwave Therapy | Intervention Type: PROCEDURE; Name: Physical therapy method called Supervised Exercises; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Radial Extracorporeal Shockwave Therapy; Assigned to Arm(s): B
B: Arm Label: Manual Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual Physical Therapy | Arm Label: Corticosteroid Injection (Subacromial); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Corticosteroid Injection | Intervention Type: PROCEDURE; Name: Manual Physical Therapy; Assigned to Arm(s): Manual Physical Therapy | Intervention Type: PROCEDURE; Name: Corticosteroid Injection; Assigned to Arm(s): Corticosteroid Injection (Subacromial)
C: Arm Label: PT progressive exercises; Type: EXPERIMENTAL; Interventions: Procedure: Exercise program | Arm Label: Movement exercises neck and shoulder; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Exercise program, Procedure: Movement exercises | Intervention Type: PROCEDURE; Name: Exercise program; Assigned to Arm(s): Movement exercises neck and shoulder, PT progressive exercises | Intervention Type: PROCEDURE; Name: Movement exercises; Assigned to Arm(s): Movement exercises neck and shoulder
D: Arm Label: Active physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy program | Arm Label: Placebo physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo physiotherapy treatment | Intervention Type: PROCEDURE; Name: Physiotherapy program; Assigned to Arm(s): Active physiotherapy | Intervention Type: PROCEDURE; Name: Placebo physiotherapy treatment; Assigned to Arm(s): Placebo physiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supervised Exercises Compared With Radial Extracorporal Shock Wave Therapy (rESWT) in Patients With Subacromial Impingement Syndrome: A Single Blind Clinical Randomized Study
Brief Summary: The purpose of this study is to compare Supervised Exercises with another non-operative frequently used treatment, Radial Extracorporeal Shockwave Therapy (rESWT), for patients with subacromial impingement syndrome.


Options:
A: Arm Label: Barbotage; Type: EXPERIMENTAL; Interventions: Procedure: Barbotage | Arm Label: Corticosteroid injection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Corticosteroid injection | Arm Label: Lidocain injection (sham); Type: SHAM_COMPARATOR; Interventions: Procedure: Lidocain injection (sham) | Intervention Type: PROCEDURE; Name: Barbotage; Assigned to Arm(s): Barbotage | Intervention Type: PROCEDURE; Name: Corticosteroid injection; Assigned to Arm(s): Corticosteroid injection | Intervention Type: PROCEDURE; Name: Lidocain injection (sham); Assigned to Arm(s): Lidocain injection (sham)
B: Arm Label: Arthroscopic Sub-acromial Decompression; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic Sub-acromial Decompression Surgery | Arm Label: Shoulder Arthroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Shoulder Arthroscopy | Arm Label: Active Monitoring with Specialist Reassessment; Type: OTHER; Interventions: Other: Active Monitoring with Specialist Reassessment | Intervention Type: PROCEDURE; Name: Arthroscopic Sub-acromial Decompression Surgery; Assigned to Arm(s): Arthroscopic Sub-acromial Decompression | Intervention Type: PROCEDURE; Name: Shoulder Arthroscopy; Assigned to Arm(s): Shoulder Arthroscopy | Intervention Type: OTHER; Name: Active Monitoring with Specialist Reassessment; Assigned to Arm(s): Active Monitoring with Specialist Reassessment
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Physical therapy method called Supervised Exercises | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radial Extracorporeal Shockwave Therapy | Intervention Type: PROCEDURE; Name: Physical therapy method called Supervised Exercises; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Radial Extracorporeal Shockwave Therapy; Assigned to Arm(s): B
D: Arm Label: Active physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy program | Arm Label: Placebo physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo physiotherapy treatment | Intervention Type: PROCEDURE; Name: Physiotherapy program; Assigned to Arm(s): Active physiotherapy | Intervention Type: PROCEDURE; Name: Placebo physiotherapy treatment; Assigned to Arm(s): Placebo physiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin.
Brief Summary: The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (\< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin glargine or NPH human insulin.


Options:
A: Arm Label: Glargine insulin; Type: EXPERIMENTAL; Interventions: Drug: Glargine insulin | Arm Label: NPH insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin | Intervention Type: DRUG; Name: Glargine insulin; Assigned to Arm(s): Glargine insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): NPH insulin
B: Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: NPH human insulin; Assigned to Arm(s): N/A
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine 300 UNT/ML | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neutral protamine hagedorn insulin | Intervention Type: DRUG; Name: Insulin Glargine 300 UNT/ML; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Neutral protamine hagedorn insulin; Assigned to Arm(s): Control
D: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Daily Consumption of Yogurt Containing Bifidobacterium Lactis (BB12) on Children's' Health and Child Care Absenteeism
Brief Summary: The aim of our study is to assess the effect of daily consumption of yogurt containing probiotic bacteria BB12 on the health and growth of healthy children 12-48 months of age in out of home child care.


Options:
A: Arm Label: fermented milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented milk | Arm Label: fermented rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented rice | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented milk; Assigned to Arm(s): fermented milk | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented rice; Assigned to Arm(s): fermented rice
B: Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Other: Yogurt drink with probiotic bacteria BB12 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Yogurt drink with probiotic bacteria BB12; Assigned to Arm(s): Probiotic | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus fermentum | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Follow on formula without probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus fermentum; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow on formula without probiotics; Assigned to Arm(s): Control
D: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Daily Consumption of Yogurt Containing Bifidobacterium Lactis (BB12) on Children's' Health and Child Care Absenteeism
Brief Summary: The aim of our study is to assess the effect of daily consumption of yogurt containing probiotic bacteria BB12 on the health and growth of healthy children 12-48 months of age in out of home child care.


Options:
A: Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Other: Yogurt drink with probiotic bacteria BB12 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Yogurt drink with probiotic bacteria BB12; Assigned to Arm(s): Probiotic | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control
B: Arm Label: Probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic
D: Arm Label: Test group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic yogurt | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic yogurt; Assigned to Arm(s): Test group | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study to Assess the Safety and Immunogenicity of New TB Vaccine Candidates FP85A and MVA85A, in Healthy Adults Who Have Previously Been Immunized With BCG, Using a Prime-boost Delivery Schedule
Brief Summary: This is a Phase I study whose primary outcome is to assess the safety of a new tuberculosis vaccine, FP85A, when administered individually and sequentially with MVA85A in a prime-boost regime, to healthy volunteers, who have previously been vaccinated with BCG. The secondary outcome is to assess the cellular immune response in the same population. The trial consists of 36 subjects in 3 groups. The first group will be vaccinated with FP85A alone, the second group will be vaccinated with MVA85A followed by FP85A 28 days later and the third group will be vaccinated with FP85A followed by MVA85A 28 days later.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: FP85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: FP85A, Biological: MVA85A | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: FP85A, Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: FP85A; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 2, 3
B: Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): N/A
C: Arm Label: MVA85A; Type: EXPERIMENTAL; Interventions: Biological: MVA85A, Biological: BCG Vaccine SSI | Arm Label: Candin; Type: ACTIVE_COMPARATOR; Interventions: Biological: Candin, Biological: BCG Vaccine SSI | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): MVA85A | Intervention Type: BIOLOGICAL; Name: Candin; Assigned to Arm(s): Candin | Intervention Type: BIOLOGICAL; Name: BCG Vaccine SSI; Assigned to Arm(s): Candin, MVA85A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: BCG | Intervention Type: BIOLOGICAL; Name: BCG; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Local Infiltration Analgesia (LIA) With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Unicompartmental Knee Arthroplasty
Brief Summary: The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. Secondary end-points are morphine consumption, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 6 months after surgery.


Options:
A: Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ropivacaine, ketorelac and epinephrine | Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: ropivacaine, ketorelac and epinephrine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): P
C: Arm Label: morphine only; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: morphine ketamine; Type: EXPERIMENTAL; Interventions: Drug: morphine ketamine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine only | Intervention Type: DRUG; Name: morphine ketamine; Assigned to Arm(s): morphine ketamine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin Complex (placebo) | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Vitamin Complex (placebo); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)
Brief Summary: The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period


Options:
A: Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only
C: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)
Brief Summary: The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period


Options:
A: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
B: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
C: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
D: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Multicenter, Trial to Assess the Effect of High & Low Doses of ZD4522 on Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects With Asymptomatic Carotid Stenosis After 24 Months of Dosing.
Brief Summary: The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.


Options:
A: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1
C: Arm Label: Dalcetrapib (RO4607381); Type: EXPERIMENTAL; Interventions: Drug: Dalcetrapib (RO4607381) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dalcetrapib (RO4607381); Assigned to Arm(s): Dalcetrapib (RO4607381) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Multicenter, Trial to Assess the Effect of High & Low Doses of ZD4522 on Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects With Asymptomatic Carotid Stenosis After 24 Months of Dosing.
Brief Summary: The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1
C: Arm Label: ENOXAPARIN 2 HOURS BEFORE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Arm Label: Enoxaparin 40 mg 12 hours before; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Intervention Type: DRUG; Name: Enoxaparin 40 mg 2 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before | Intervention Type: DRUG; Name: Enoxaparin 40 mg 12 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before
D: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Multicenter, Trial to Assess the Effect of High & Low Doses of ZD4522 on Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects With Asymptomatic Carotid Stenosis After 24 Months of Dosing.
Brief Summary: The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1
B: Arm Label: 40 mg subcutaneous enoxaparin o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: 40 mg subcutaneous enoxaparin b.i.d; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): 40 mg subcutaneous enoxaparin b.i.d, 40 mg subcutaneous enoxaparin o.d.
C: Arm Label: Investigational arm; Type: EXPERIMENTAL; Interventions: Drug: Heparin | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Investigational arm
D: Arm Label: thrombose prophylaxis; Type: N/A; Interventions: Drug: Dose of Tinzaparin or Dalteparin | Arm Label: double thrombose prophylaxis; Type: N/A; Interventions: Drug: Dose of Tinzaparin or Dalteparin | Arm Label: full dose anticoagulant; Type: N/A; Interventions: Drug: Dose of Tinzaparin or Dalteparin | Intervention Type: DRUG; Name: Dose of Tinzaparin or Dalteparin; Assigned to Arm(s): double thrombose prophylaxis, full dose anticoagulant, thrombose prophylaxis

Answer: A